The most important prescribing information of Bevarest is; Metastatic colorectal cancer Non-squamous non-small cell lung cancer Recurrent Glioblastoma Advanced renal cell cancer Advanced cervical cancer Epithelial ovarian, fallopian tube or primary peritoneal cancer
Bevacizumab link to the VEGF and inhibits the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The combination of VEGF with its receptors causesendothelial cell replication and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
Brand : Bevarest
Ingredients : Bevacizumab
Strength : 100mg/4ml
Manufactured : Emcure
Package : one vial in a carton
The most important administration factors are, Bevarest should not be used until at least 28 days following surgery and lesion is completely healed.Metastatic colon rectal cancer
The prescribed dose when Bevarest is administered in co administration with intravenous 5-fluorouracil-based chemotherapy is: Patient Administrate 5 mg/kg every 2 weeks intravenously in combination with bolus-IFL. Patient Administrate 10 mg/kg every 2 weeks intravenously in combination with FOLFOX4. Patient Administrate 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Bevarest -containing regimen.Non-squamous non-small cell lung cancer
The usual dose of Bevarest is 15mg/kg should be administered via IV for every 2 weeks by interaction with carboplatin & paclitaxel.Recurrent Glioblastoma
The usual dose of Bevarest is 10mg/kg should be administered IV for every 2 weeksAdvanced renal cell cancer
The usual suggested dose of Bevarest is 10mg/kg should be given intravenously for every 2 weeks by co administration with interferon alfa.Advanced cervical cancer
The prescribed dose of Bevarest in this condition is 15mg/kg of drug should be given intravenously for every 3 weeks by interaction with paclitaxel & cisplatin or by combining with paclitaxel & topotecan.Epithelial ovarian, fallopian tube, or peritoneal cancer
Therapy of stage III or IV: The usual dose of Bevarest is 15mg/kg IV for every 3 weeks by concomitant with carboplatin & paclitaxel for period of 6 cycles, continued by Bevarest 15mg/kg for every 3 weeks as a single regimen, for total duration of treatment is 22 cycles.Administration
Bevarest should be givenvia intravenous infusion over the period of 90 minutes as first infusion and consecutive infusions may follow over 60 minutes. 100mg of Bevarest containing 4ml solution which is diluted in 100ml of 0.9% sodium chloride solution. Bevarest should not be diluted in dextrose solution. Bevarest should be administered as intravenous site. It should be administered with or without food.OVERDOSE
There is no chance of getting over dosage in Bevarest getting patients, because Bevarest is a cytotoxic drug which is administered only under the supervision of medical oncologist. Bevarest should be used cautiously.
GI perforations & fistulae, Surgery and wound healing complications, Hemorrhage, Arterial thromboembolic events, Venous thromboembolic events, Hypertension, Posterior reversible encephalopathy syndrome, Renal damage & Proteinuria, Infusion reactions, Ovarian failure, Congestive heart failure
Some warning signs should be taken into consideration; Gastrointestinal perforation, surgery & wound lesions complexity or hemorrhages are the major adverse effect occurs during the treatment with Bevarest injection.Hypertension
Increased blood pressure in patients who are receiving Bevarest therapy, should be monitor frequently with blood pressure and provided with alternative medication for correct the pressure. In hypertension crisis or encephalopathy should be discontinue the treatment.Arterial thromboembolic events
Discontinue the therapy with Bevarest in patients who are suffered with severe ATE. Venous thromboembolic events: Incidence of toxicity should be detected; in case of severe condition therapy should be stopped.In GI perforation
Treatment should be discontinued and providing supportive measures In wound or surgery complications: Bevarest treatment should be interrupt during the surgery until the wound should be completely healed. Nearly 28 days after & before the surgery, therapy should be withheld.Hemorrhage
Severe hemorrhages like GI bleeding, hemoptysis, Hematemesis, CNS hemorrhage, Epistaxis & vaginal bleeding are occurring during the Bevarest treatment. Discontinue the treatment.Posterior reversible encephalopathy syndrome
Symptoms should be cleared with providing supportive measures after discontinuing the Bevarest therapy and PRES should be monitored by undergoing MRI. In severe condition, patients should be discontinuing with Bevarest treatment.In renal injury & Proteinuria
Toxicity grade should be resolved by monitoring the renal function and Proteinuria. Infusion reactions: In severe infusion reactions, patients should not take Bevarest treatment.Embryo fetal damage
Bevarest is contraindicated to pregnancy condition, produce fetal harm.Ovarian failure
Bevarest receiving patients may have a chance of getting ovarian failure.Congestive heart failure
In anthracycline based chemotherapy, Bevarest treatment should not be used. Bevarest treatment should be discontinuing while CHF occurs.
Bevarest interaction with paclitaxel & carboplatin causes decrease exposure of paclitaxel after completion of 4 cycles of therapy. When patients getting paclitaxel & carboplatin as alone, causes elevation of paclitaxel exposure at day 63.